文献速递水电解质与酸碱血液净化与透析

替纳帕诺在日本血液透析高磷血症患者中的剂量效应——一项2期随机试验

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial.
PubMed 文献 · Kidney Int Rep · 2021-11-24

这项多中心2期双盲安慰剂对照平行组剂量探索研究纳入207例日本血液透析高磷血症患者,随机分为安慰剂组及替纳帕诺5mg每日两次、10mg每日两次、30mg每日两次、30mg每日两次剂量滴定组治疗6周。第6周血清磷较基线变化分别为0.64、-0.93、-1.36、-1.92、-1.99 mg/dl,各替纳帕诺组较安慰剂均显著降低(P<0.001)。腹泻为最常见药物相关不良事件,各剂量组发生率9.8%至76.2%,多为轻度和可耐受。

要点

  • 替纳帕诺呈剂量依赖性降低血清磷水平,各剂量组较安慰剂均显著降低(P<0.001)。
  • 腹泻为最常见药物相关不良事件,安慰剂组9.8%,替纳帕诺组50.0%至76.2%。
  • 多数腹泻病例为轻度且一般可耐受。

核心结论

  • 替纳帕诺在日本血液透析患者中具有剂量依赖性的降血清磷作用,可能成为高磷血症的首创治疗药物。

研究设计与样本

  • 多中心、2期、双盲、安慰剂对照、平行组、剂量探索研究。
  • 共207例患者随机分为5组:安慰剂组(n=41)、替纳帕诺5mg每日两次组(n=42)、10mg每日两次组(n=41)、30mg每日两次组(n=42)、30mg每日两次剂量滴定组(n=41),治疗6周。
  • 主要终点为第6周血清磷较基线的变化。

主要发现

  • 第6周血清磷较基线平均变化:安慰剂组0.64 mg/dl,替纳帕诺5mg每日两次组-0.93 mg/dl,10mg每日两次组-1.36 mg/dl,30mg每日两次组-1.92 mg/dl,30mg每日两次剂量滴定组-1.99 mg/dl。
  • 各替纳帕诺组血清磷较基线降低均显著优于安慰剂(P<0.001)。
  • 药物相关不良事件中腹泻最常见,发生率分别为安慰剂组9.8%、替纳帕诺5mg每日两次组50.0%、10mg每日两次组65.9%、30mg每日两次组76.2%、30mg每日两次剂量滴定组65.9%。
  • 多数腹泻病例为轻度且一般可耐受。

关键数值与推荐

  • 各替纳帕诺组较安慰剂血清磷降低均P<0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Simplified, but effective, hyperphosphatemia treatments with novel mechanisms of action, tolerable safety profiles, and low pill burden are needed for patients undergoing hemodialysis. Tenapanor is a calcium (Ca)-free, nonmetal, nonpolymeric drug that reduces phosphate absorption by selectively inhibiting intestinal sodium-hydrogen exchanger 3. As the serum phosphorus (P) level-lowering effect of tenapanor has not been evaluated in Japanese patients with hyperphosphatemia undergoing hemodialysis, we evaluated its efficacy and safety in this population. METHODS: This was a multicenter, phase 2, double-blind, placebo-controlled, parallel-group, dose-finding study. Change in serum P level from baseline at week 6 was the primary end point. RESULTS: Overall, 207 patients were randomized to 5 groups (placebo [n = 41] and tenapanor 5-mg taken twice daily [BID] [n = 42], 10-mg BID [n = 41], 30-mg BID [n = 42], and 30-mg BID dose-titration [n = 41]) and treated for 6 weeks. Mean changes from baseline at week 6 in serum P level were 0.64, -0.93, -1.36, -1.92, and -1.99 mg/dl in the placebo and tenapanor groups, respectively. Serum P level was significantly decreased from baseline in all tenapanor groups compared with placebo (P < 0.001, for each dose). Diarrhea was the most frequent drug-related adverse event (AE) with an incidence of 9.8%, 50.0%, 65.9%, 76.2%, and 65.9% in the respective placebo and tenapanor groups. CONCLUSION: In Japanese patients undergoing hemodialysis, tenapanor was found to have a dose-responsive, serum P level-lowering effect. Diarrhea was the most frequent drug-related AE; most cases were mild and generally tolerable. Tenapanor may become a first-in-class therapeutic agent for patients with hyperphosphatemia.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Inaba M, Une Y, Ikejiri K, et al. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. Kidney Int Rep. 2021. PMID: 35155857. doi:10.1016/j.ekir.2021.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。